ARTICLE SUMMARY:
Our most-read articles in 2022: Talking strategy with J&J MedTech and Edwards Lifesciences; new digital therapeutics for Alzheimer's disease; using AI to diagnose GI disorders; and how to price products in a digital world.
The top five MedTech Strategist articles in 2022.
Subscribers, click through to read the full articles. Non-subscribers, take advantage of our free trial offer.
#1: Charting the Future at Johnson & Johnson MedTech: An Interview with Ashley McEvoy
Ashley McEvoy, head of J&J’s MedTech business, talks about the current state of the company’s medical device businesses, the impact of the COVID pandemic, and what the future holds for J&J MedTech.
#2: Digital Therapeutics for Alzheimer’s Blur Industry Boundaries
Alzheimer’s disease has long been the sole province of pharmaceutical and biotech companies, but digital therapeutics companies are on their way to proving that with platforms offering a high safety profile, their approaches are disease-modifying, even on a stand-alone basis. If these digital therapeutics halt or even slow down disease progression, they’ll provide enormous value to the healthcare system.
#3: AI Makes Waves in Gastroenterology: Can It Help Democratize Care?
Artificial intelligence has emerged as a valuable tool in diagnostic imaging, where machine-learning algorithms applied to image-based scans are helping physicians rapidly and accurately detect and diagnose diseases such as diabetic retinopathy, cancer, and stroke. Now, AI is branching into video endoscopy and could help level the playing field for patients with a number of GI disorders.
#4: Optimizing Medtech Pricing Flexibility in a Digital World: Subscription Versus CapEx
As medtech companies modify their business practices and pricing models to draw out the maximum value of their integrated digital and medical device offerings and respond to customers’ concerns about high up-front costs of adopting new technologies, they need to discern the trade-offs and proper use cases.
#5: Edwards Lifesciences: 20 Years After
After its spin-off from Baxter in 2000, Edwards’ strategy was more “Don’t make waves” than “Shake things up.” But the promise of transcatheter valve replacement was too great and now, two decades after the launch of its TAVR program, Edwards stands atop the cardiovascular device industry. A roundtable discussion with Mike Mussallem, Larry Wood, and Bernard Zovighian.
Trial MyStrategist.com and unlock 7-days of exclusive subscriber-only access to the medical device industry's most trusted strategic publications: MedTech Strategist & Market Pathways. For more information on our demographics and current readership click here.
